Comparison between lymph and non-lymph node resection in patients with stage IA non-small-cell lung cancer: A retrospective study.

Bao Lei, Zhiping Zhang, Chunxia Li, Jiao Yang, Jing Peng, Yanqiu Zhao, Guiming Liu, Han Liang, Jun Feng, Xudong Xiang
{"title":"Comparison between lymph and non-lymph node resection in patients with stage IA non-small-cell lung cancer: A retrospective study.","authors":"Bao Lei, Zhiping Zhang, Chunxia Li, Jiao Yang, Jing Peng, Yanqiu Zhao, Guiming Liu, Han Liang, Jun Feng, Xudong Xiang","doi":"10.4103/jcrt.jcrt_131_24","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>This retrospective study aimed to determine the need for lymph node resection during surgical treatment in patients with stage IA non-small-cell lung cancer (NSCLC).</p><p><strong>Materials and methods: </strong>A total of 1428 patients diagnosed with cT1N0M0 1 A stage NSCLC who underwent surgery were divided into two groups: lymphadenectomy (n = 1324) and nonlymphadenectomy (n = 104). The effects of lymph node resection on overall survival (OS) and recurrence-free survival (RFS) and on clinicopathological factors that affected the prognosis of the patients were investigated.</p><p><strong>Results: </strong>The group that underwent lymph node resection had a better 5-year OS (89.2% vs 81.1%) and 3-year RFS (87.6% vs 79.2%) than the one that did not. Multivariate Cox regression analysis revealed that the risk of OS in the nonlymphadenectomy group increased by 72% compared to that in the lymphadenectomy group [hazard ratio (HR), 1.72; 95% confidence interval (CI), 1.08-2.74; P < 0.05]. The risk of RFS in the group without lymphadenectomy increased by 45% compared to that in the group with lymphadenectomy (HR, 1.45; 95% CI, 0.98-2.14;P = 0.06). Significant reductions in the OS (HR, 5.90; 95% CI, 1.80-20.00; P < 0.005) and RFS (HR, 4.00; 95% CI, 1.50-11.00;P < 0.005) can be seen in the absence of lymph node resection in NSCLC patients with emphysema.</p><p><strong>Conclusion: </strong>A thorough evaluation and removal of the hilar and mediastinal lymph nodes may prove useful in determining the cancer stage and assessing the need for further treatment, thus enhancing the prognosis of patients with stage IA NSCLC.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"20 7","pages":"2094-2102"},"PeriodicalIF":0.0000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of cancer research and therapeutics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/jcrt.jcrt_131_24","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/10 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: This retrospective study aimed to determine the need for lymph node resection during surgical treatment in patients with stage IA non-small-cell lung cancer (NSCLC).

Materials and methods: A total of 1428 patients diagnosed with cT1N0M0 1 A stage NSCLC who underwent surgery were divided into two groups: lymphadenectomy (n = 1324) and nonlymphadenectomy (n = 104). The effects of lymph node resection on overall survival (OS) and recurrence-free survival (RFS) and on clinicopathological factors that affected the prognosis of the patients were investigated.

Results: The group that underwent lymph node resection had a better 5-year OS (89.2% vs 81.1%) and 3-year RFS (87.6% vs 79.2%) than the one that did not. Multivariate Cox regression analysis revealed that the risk of OS in the nonlymphadenectomy group increased by 72% compared to that in the lymphadenectomy group [hazard ratio (HR), 1.72; 95% confidence interval (CI), 1.08-2.74; P < 0.05]. The risk of RFS in the group without lymphadenectomy increased by 45% compared to that in the group with lymphadenectomy (HR, 1.45; 95% CI, 0.98-2.14;P = 0.06). Significant reductions in the OS (HR, 5.90; 95% CI, 1.80-20.00; P < 0.005) and RFS (HR, 4.00; 95% CI, 1.50-11.00;P < 0.005) can be seen in the absence of lymph node resection in NSCLC patients with emphysema.

Conclusion: A thorough evaluation and removal of the hilar and mediastinal lymph nodes may prove useful in determining the cancer stage and assessing the need for further treatment, thus enhancing the prognosis of patients with stage IA NSCLC.

IA期非小细胞肺癌患者淋巴结与非淋巴结切除术的比较:一项回顾性研究。
目的:本回顾性研究旨在确定IA期非小细胞肺癌(NSCLC)患者在手术治疗期间是否需要淋巴结切除术。材料与方法:1428例经手术诊断为ct1n0m1a期非小细胞肺癌患者分为两组:淋巴结切除术(n = 1324)和非淋巴结切除术(n = 104)。探讨淋巴结切除术对总生存期(OS)、无复发生存期(RFS)及影响患者预后的临床病理因素的影响。结果:行淋巴结切除术组的5年OS (89.2% vs 81.1%)和3年RFS (87.6% vs 79.2%)优于未行淋巴结切除术组。多因素Cox回归分析显示,与淋巴结切除术组相比,非淋巴结切除术组发生OS的风险增加了72%[风险比(HR), 1.72;95%置信区间(CI), 1.08-2.74;P < 0.05]。与行淋巴结切除术组相比,未行淋巴结切除术组发生RFS的风险增加了45% (HR, 1.45;95% ci, 0.98-2.14; p = 0.06)。OS显著降低(HR, 5.90;95% ci, 1.80-20.00;P < 0.005)和RFS (HR, 4.00;95% CI, 1.50-11.00;P < 0.005),非小细胞肺癌合并肺气肿患者未行淋巴结切除术。结论:彻底评估和切除肺门和纵隔淋巴结可能有助于确定癌症分期和评估进一步治疗的需要,从而改善IA期NSCLC患者的预后。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信